医学
组织学
Glypican 3型
肝母细胞瘤
肝细胞癌
病理
化疗
免疫染色
细胞角蛋白
免疫分型
胃肠病学
免疫组织化学
内科学
免疫学
流式细胞术
作者
Shengmei Zhou,Rajkumar Venkatramani,Shveta Gupta,Kasper Wang,James E. Stein,Larry Wang,Leo Mascarenhas
摘要
Aims The primary aim of this study is to characterize hepatocellular malignant neoplasm, NOS ( HEMNOS ), a new provisional entity describing a subset of paediatric hepatocellular tumours, which have histological features of neither typical hepatoblastoma ( HB ) nor hepatocellular carcinoma ( HCC ). Methods and results The clinicopathological features of 11 patients with HEMNOS were analysed retrospectively. The median age and serum alpha‐fetoprotein level at diagnosis was 7 years and 182 000 ng/ml, respectively. Ten patients presented with pretreatment extent of disease ( PRETEXT ) stages III / IV multifocal tumours, eight with major vascular involvement, three with lung metastases and three with extrahepatic extension. The original pathology diagnoses were: HB in seven patients, HCC in two and HEMNOS in two. Our pathology review of pre‐chemotherapy specimens showed that six tumours had equivocal/overlapping histological features of HB and HCC , four had predominant HB histology along with focal HCC ‐like histology and one had HB histology. Seven of nine post‐chemotherapy resection specimens showed predominant HCC ‐like histology. Beta‐catenin, glypican 3 and spalt‐like transcription factor 4 immunostaining showed that all the tumours had a mixed HB / HCC immunophenotype. Telomerase reverse transcriptase immunostaining showed nuclear staining in nine of the 11 tumours. All patients received chemotherapy and achieved gross total primary tumour resection. Nine of the 11 patients were treated with established HB chemotherapy regimens. After a median follow‐up of 6.1 years (range: 1.2–11.8 years), all patients were in remission. Conclusions HEMNOS is a subtype of HB with focal HCC ‐like histology, a high‐risk clinical profile but favourable outcome following chemotherapy and complete tumour resection.
科研通智能强力驱动
Strongly Powered by AbleSci AI